Cigna’s PBM Express Scripts sues the FTC, seeking retraction of drug-cost report
Cigna Group’s pharmacy benefit manager Express Scripts on Tuesday sued the U.S. Federal Trade Commission, alleging that the agency’s July report on the PBM industry was biased and defamatory and asking the court to order the FTC to withdraw the report.
Express Scripts sues FTC over report scrutinizing PBM practices
As the FTC has increasingly prodded PBMs over their role in high drug costs, Express Scripts is fighting back by launching a lawsuit against the agency.
Express Scripts sues FTC over 'flawed and biased' PBM report
Express Scripts parent company Cigna alleges the Federal Trade Commission ignored more than 3 million pages of documents the pharmacy provided to investigators.
PBM strikes back at FTC over drug pricing report
The complaint, filed by Express Scripts owner Cigna against the FTC and Commissioner Lina Khan, is seeking the retraction of the report, which the company claims is "unfair, biased, erroneous, and defamatory" against the PBM industry and is "seventy-four pages of unsupported innuendo."
Express Scripts files suit against FTC, demands retraction of report on PBM industry
Express Scripts has filed suit against the Federal Trade Commission, demanding that the agency retract a damning report on the pharmacy benefit management industry. | Express Scripts has filed suit against the Federal Trade Commission,
Cigna's Express Scripts sues FTC over 'defamatory' PBM report
Cigna's Express Scripts, one of the country's largest pharmacy benefit managers, today sued the Federal Trade Commission and its chair, Lina Khan, over what the company asserts was a report filled with false and misleading claims about how pharmacy benefit management firms operate.
Express Scripts Sues FTC to Withdraw its PBM Report
Express Scripts alleges in its suit that the FTC followed “prejudice and politics, not evidence or sound economics,” and that there is no support for the assertion that the power of PBMs has increased over time.
Express Scripts Sues FTC Over PBM Report
Express Scripts is suing the Federal Trade Commission (FTC), demanding the retraction of a report it claims is false and harmful to the pharmacy benefit manager (PBM) industry.
Express Scripts sues FTC and demands drug pricing report retraction
The US-based pharmacy benefit manager (PBM) claims that the FTC’s July 2024 report is riddled with “false and misleading claims” about the PBM industry.
Cigna's Express Scripts Sues FTC, Demands Withdrawal Of PBM Report; Stock Down
Express Scripts by Evernorth, a unit of Cigna Group (CI), Tuesday said it has filed a lawsuit against the Federal Trade Commission or
Express Scripts sues FTC over a ‘biased’ report about pharmacy benefit managers
Express Scripts, one of the largest pharmacy benefit managers in the U.S., filed a lawsuit demanding that a recent FTC report on industry middlemen be vacated.
The American Journal of Managed Care1h
FTC Takes Legal Action Against 3 Largest PBMs Over Insulin Costs
The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the ...
Pharmacy Benefit Management (PBM) Market to Surpass USD 934.9 billion by 2032 Driven by Innovation and Healthcare Spending
Market is Growing at CAGR of 6.0%, Increasing Demand for Cost-Effective Drug Management Solutions Propels Market Growth.Pune, ...
Insurancenewsnet.com1d
Senate chair wants to see PBM reform bill passed this year
Pharmacy benefit manager reform, prescription drug costs and ACA tax credits were discussed by the Senate Finance Committee.
Times-News3h
New Idaho law to reform pharmacy middlemen aims to lower drug costs
A recent report by federal regulators said PBMs drive up costs. U.S. Sen. Mike Crapo, R-Idaho, has pushed for federal PBM ...
Niagara Gazette4dOpinion
FARROW: Two separate reports sound alarm on PBM practices that harm patients, consumers
Consumers should be alarmed by two independent reports that accuse pharmacy benefit managers, the influential middlemen in ...
Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq
Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on September 12, 2024, the Company received a staff determination letter (the “Determination Letter”) from the Listing ...